



7934 Government Road, Burnaby, B.C., V5A 2E2

Phone: (604) 551-7831 Fax: 604-676-2767

info@cannabixtechnologies.com

cannabixtechnologies.com

Cannabix Technologies Announces Results of AGM and Special Meeting

Vancouver, British Columbia, February 17, 2015 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF), developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace announces the results of its annual general and special meeting of common shareholders held on February 17, 2015 in Vancouver. Resolutions passed at the meeting included the re-appointment of Manning Elliot Chartered Accountants LLP as auditors, approval of the company's incentive stock option plan, shareholder approval of the plan of arrangement to transfer 100% of the Monster Lake South gold property and \$10,000 cash to Spinco (Torino Ventures Inc.) in consideration for the issuance of eight million common shares of Spinco, and to distribute these common shares to the company's shareholders on a pro rata basis pursuant to a plan of arrangement under the Business Corporations Act (British Columbia). Furthermore, the following directors were elected by shareholders: Rav Mlait, Bryan Loree, Kal Malhi, Raj Attariwala and Thomas Clarke.

Kal Malhi, President of Cannabix Technologies stated, "Our team continues to work with engineering firm KLN Klein Product Development to optimize the Cannabix Marijuana Breathalyzer prototype for release in a timely manner. We have been pleased by the most recent media recognition Cannabix has received over the last week or so with Portland Oregon's ABC affiliate KATU 2 (KATU.COM) and CTV National News (Canada) highlighting Cannabix Technologies and its developing marijuana breathalyzer."

We seek Safe Harbor.

For more information visit cannabixtechnologies.com

About Cannabix Technologies Inc.

[Cannabix Technologies Inc.](http://CannabixTechnologiesInc.com) is the developer of the patent pending Cannabix Marijuana Breathalyzer for law enforcement and the workplace. The Cannabix Marijuana Breathalyzer drug-impairment recognition system is based on breath testing technology that has been developed to test individuals for recent consumption of the THC component of marijuana. Cannabix is advancing its products to enable law enforcement personnel to use this technology to enhance detection of marijuana impaired driving offences on North American roads at a time when marijuana is becoming legal in many jurisdictions. Cannabix is working to develop a drug-testing device that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. The device would be used to provide detection of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. The device will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous. The device is currently in prototype development.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.